We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+4.24%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.94B
AUM Growth
-$224M
Cap. Flow
-$1.92B
Cap. Flow %
-24.14%
Top 10 Hldgs %
74.98%
Holding
115
New
11
Increased
21
Reduced
12
Closed
7

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$30.4M
2
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$19.4M
3
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$16.5M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$15.8M
5
XNPT
XENOPORT, INC.
XNPT
+$13.6M

Top Sells

Rank Stock Value
1
ITMN
INTERMUNE INC
ITMN
+$209M
2
QCOR
QUESTCOR PHARMA INC
QCOR
+$46.2M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$32.8M
4
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$18.1M
5
AEGR
Aegerion Pharmaceuticals
AEGR
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 39.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCYC
1
DELISTED
PHARMACYCLICS INC
PCYC
$1.13B 14.28%
9,656,599
+65,053
+0.7% +$7.41M
SGEN
2
DELISTED
Seagen Inc. Common Stock
SGEN
$836M 10.52%
22,475,729
+3,500
+0% +$138K
GEVA
3
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$733M 9.23%
10,660,432
– –
INCY icon
4
Incyte
INCY
$25.4B
$728M 9.17%
14,845,559
– –
ACAD icon
5
Acadia Pharmaceuticals
ACAD
$4.47B
$507M 6.39%
20,481,442
– –
GHDX
6
DELISTED
Genomic Health, Inc.
GHDX
$387M 4.87%
13,655,618
+716
+0% +$20K
AVNR
7
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$250M 3.15%
20,974,677
+2,416,190
+13% +$16.5M
BMRN icon
8
BioMarin Pharmaceuticals
BMRN
$11.8B
$171M 2.15%
2,370,464
+462,234
+24% +$30.4M
AVNR
9
CALL
DELISTED
AVANIR PHARMACEUTICALS, INC CL A
AVNR
$112M 1.4%
+9,356,200
New +$63.9M
BCRX icon
10
BioCryst Pharmaceuticals
BCRX
$2.42B
$105M 1.32%
10,713,686
-177,186
-2% -$2.17M
ANAC
11
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$103M 1.3%
4,204,702
+956,659
+29% +$19.4M
XOMA
12
DELISTED
Xoma
XOMA
$97.1M 1.22%
1,153,574
+275
+0% +$23.5K
DYAX
13
DELISTED
DYAX CORPORATION
DYAX
$62.3M 0.78%
6,157,789
+476,552
+8% +$4.62M
CERS icon
14
Cerus
CERS
$569M
$47.9M 0.6%
11,940,178
+1,693,587
+17% +$6.51M
VNDA icon
15
Vanda Pharmaceuticals
VNDA
$303M
$45.4M 0.57%
4,372,153
– –
MRTX
16
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$41.7M 0.52%
2,380,074
– –
XNPT
17
DELISTED
XENOPORT, INC.
XNPT
$36.7M 0.46%
6,815,777
+2,781,665
+69% +$13.6M
DSCI
18
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$29.5M 0.37%
3,537,137
– –
RPRX
19
DELISTED
Repros Therapeutics Inc.
RPRX
$27.5M 0.35%
2,778,654
– –
GILD icon
20
Gilead Sciences
GILD
$165B
$27.3M 0.34%
256,108
– –
ACOR
21
DELISTED
Acorda Therapeutics
ACOR
$25.5M 0.32%
6,278
-1,273
-17% -$4.78M
HALO icon
22
Halozyme
HALO
$9.9B
$25.3M 0.32%
2,776,143
– –
ARAV
23
DELISTED
Aravive, Inc. Common Stock
ARAV
$23.7M 0.3%
207,682
+34
+0% +$4.5K
PGNX
24
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$23.1M 0.29%
4,449,797
– –
CPRX
25
DELISTED
Catalyst Pharmaceutical
CPRX
$22.3M 0.28%
6,715,462
+4,492,409
+202% +$11.7M
1
2 3 4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q3 2014 Portfolio in Review

As of Q3 2014, Baker Bros. Advisors held 115 positions worth $7.94B, down 2.7% from $8.16B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Baker Bros. Advisors withdrew a net $1.92B in Q3 2014, closing 7 positions and reducing 12 holdings. Its most notable exit was INTERMUNE INC, an estimated $209M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 40% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in MALLINCKRODT PUBLIC LIMITED COMPANY worth $18.2M.

  • Baker Bros. Advisors's largest Q3 2014 buy was MALLINCKRODT PUBLIC LIMITED COMPANY: 201,856 shares worth $18.2M.
  • Baker Bros. Advisors added most to BioMarin Pharmaceuticals in Q3 2014, an estimated $30.4M increase.
  • Baker Bros. Advisors's biggest Q3 2014 reduction was SALIX PHARMACEUTICALS LTD DEL, cutting an estimated $18.1M.
  • Baker Bros. Advisors fully exited INTERMUNE INC in Q3 2014, selling an estimated $209M.
  • Baker Bros. Advisors's ten largest holdings make up 75% of its $7.94B portfolio in Q3 2014.
  • Baker Bros. Advisors opened 11 new positions and closed 7 in Q3 2014.
  • Baker Bros. Advisors's portfolio value fell 2.7% quarter-over-quarter to $7.94B.

Based on Baker Bros. Advisors's 13F filing for Q3 2014, filed 14 Nov 2014.